Recent Updates
Recently added Catalysts
NVAX

Novavax to Present at the 28th Annual Piper Jaffray Healthcare Conference

Key Takeaway: GAITHERSBURG, Md., Nov. 22, 2016 (GLOBE NEWSWIRE) -- Novavax, Inc., (Nasdaq:NVAX) today announced Stanley C Erck, President and Chief Executive Officer, will present at the 28th Annual Piper Jaffray Healthcare Conference. Conference details are as follows: Date: Tuesday, Novemb

BiopharmaWatch Analysis

From our catalyst data and publicly available data · not financial advice
Cash runway
~29 mo
Minimal dilution risk
Lead asset
SARS-CoV-2 rS/Matrix-M1 Adjuvant
Phase 3 · SARS-CoV-2 Infection

Full Press Release Details

GAITHERSBURG, Md., Nov. 22, 2016 (GLOBE NEWSWIRE) -- Novavax, Inc., (Nasdaq:NVAX) today announced Stanley C Erck, President and Chief Executive Officer, will present at the 28th Annual Piper Jaffray Healthcare Conference.
Conference details are as follows:
Date: Tuesday, November 29, 2016
Time: 3:30 pm U.S. Eastern Time
Location: New York Palace Hotel, New York, New York
Live webcast: novavax.com, “Investors”/ “Events”
A replay of the presentation will also be accessible under the “Investors/Events” section of the Novavax website at novavax.com.
Novavax, Inc. (Nasdaq:NVAX) is a clinical-stage vaccine company committed to delivering novel products to prevent a broad range of infectious diseases. Our recombinant nanoparticles and Matrix-M™ adjuvant technology are the foundation for groundbreaking innovation that improves global health through safe and effective vaccines. Additional information about Novavax is available on the Company's website, novavax.com.
Last updated: Nov 22, 2016